Related Experiment Video

Updated: May 17, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications

Paulo Caleb Junior Lima Santos1, Jose Eduardo Krieger, Alexandre Costa Pereira

  • 1Laboratory of Genetics and Molecular Cardiology, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.

Journal of Pharmacological Sciences
|October 20, 2012
PubMed

Insights

Chronic kidney disease (CKD) and hypertension involve a vicious cycle driven by the renin-angiotensin system (RAS). Exploring RAS gene variations could personalize treatments for better blood pressure control and kidney protection.

Area of Science:

  • Nephrology
  • Pharmacogenetics
  • Cardiovascular Medicine

Background:

  • Hypertension is prevalent in chronic kidney disease (CKD) patients, forming a detrimental cycle impacting kidney function.
  • Hyperactivity of the renin-angiotensin system (RAS) exacerbates renal damage in this context.
  • Current guidelines recommend RAS blockade for hypertension, but treatment response and renal protection vary significantly among individuals.

Purpose of the Study:

  • To review the genetic characteristics of renin-angiotensin system components.
  • To identify potential pharmacogenetic implications of RAS-blocker therapies in hypertension and CKD.
  • To highlight the need for further pharmacogenetic research in this patient population.

Main Methods:

  • Literature review focusing on genetic polymorphisms within the renin-angiotensin system.
  • Analysis of existing pharmacogenetic studies related to RAS-blocker drugs.
  • Examination of studies specifically investigating the hypertension-CKD scenario.

Main Results:

  • Consistent associations between RAS polymorphisms and antihypertensive response are currently lacking.
  • Research specifically on pharmacogenetics in CKD patients is scarce.
  • Inter-individual variability in treatment response and renal protection persists.

Conclusions:

  • Pharmacogenetic studies of RAS-blocker drugs warrant further investigation in the context of hypertension and CKD.
  • Newer genetic tools may offer enhanced insights.
  • Future research should prioritize both antihypertensive efficacy and renal protective outcomes.

More Related Videos

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.